| Literature DB >> 28626522 |
Ryan J Yoder1, Qinggeng Zhuang2, Jeremy M Beck2, Andrew Franjesevic2, Travis G Blanton1, Sydney Sillart2, Tyler Secor2, Leah Guerra2, Jason D Brown2, Carolyn Reid2, Craig A McElroy3, Özlem Doğan Ekici4, Christopher S Callam2, Christopher M Hadad2.
Abstract
Acetylcholinesterase (AChE) is an essential enzyme that can be targeted by organophosphorus (OP) compounds, including nerve agents. Following exposure to OPs, AChE becomes phosphylated (inhibited) and undergoes a subsequent aging process where the OP-AChE adduct is dealkylated. The aged AChE is unable to hydrolyze acetylcholine, resulting in accumulation of the neurotransmitter in the central nervous system (CNS) and elsewhere. Current therapeutics are only capable of reactivating inhibited AChE. There are no known therapeutic agents to reverse the aging process or treat aged AChE. Quinone methides (QMs) have been shown to alkylate phosphates under physiological conditions. In this study, a small library of novel quinone methide precursors (QMPs) has been synthesized and examined as potential alkylating agents against model nucleophiles, including a model phosphonate. Computational studies have been performed to evaluate the affinity of QMPs for the aged AChE active site, and preliminary testing with electric eel AChE has been performed.Entities:
Keywords: Acetylcholinesterase; organophosphorus chemical nerve agents; quinone methide
Year: 2017 PMID: 28626522 PMCID: PMC5467195 DOI: 10.1021/acsmedchemlett.7b00037
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345